Biorithm

Focus: Biorithm is a Singapore-based biotechnology company specializing in fetal monitoring devices, particularly cardiotocography (CTG) alternatives and fetal ECG monitoring systems. The company operates at an early clinical stage with a focused portfolio in pregnancy-related diagnostics.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Biorithm

AI assessmentNot Hiring

No open roles listed right now. Follow Biorithm to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Femom System

Pregnancy monitoring (alternative to CTG)

Pre-Commercial

Lead device under clinical evaluation against standard-of-care cardiotocography in 1 active trial.

Fetal ECG Monitoring System

High-risk pregnancy monitoring

Help build intelligence for Biorithm

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to shape early-stage medical device innovation in an underserved obstetrics space with 4 active clinical trials
Singapore location offers access to growing Asia-Pacific healthcare market and regulatory pathways
Early-stage company position enables direct impact on product development and strategic decisions

Watch Out For

No current active job openings (0 positions listed) suggests limited near-term hiring or early organizational scaling phase
Minimal public financial data, clinical trial phase information, and funding details create visibility risk for career planning
Pre-revenue status with early-stage clinical programs indicates extended timeline to commercial inflection and potential job security

Generated by Claude from Biorithm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Secondary focus device with 1 active trial in high-risk pregnancy population.

Pipeline & Clinical Trials

Femom System Compared to the Standard of Care CTG

Pregnancy Related

N/A

Clinical Trials (1)

NCT06490471Femom System Compared to the Standard of Care CTG

N/A

Fetal ECG monitoring

High Risk Pregnancy

N/A

Clinical Trials (1)

NCT06822439Remote Fetal Monitoring in High Risk Pregnancies

N/A

AMBulatory Fetal ECG Monitoring in Low and High-Risk Pregnancies

Pregnancy Related

N/A

Clinical Trials (1)

NCT06497205AMBulatory Fetal ECG Monitoring in Low and High-Risk Pregnancies

N/A

This Clinical Study Evaluates the Performance and Safety of Biorithm Research Kit Versus CTG in Pren

Pregnancy

N/A

Clinical Trials (1)

NCT04941534This Clinical Study Evaluates the Performance and Safety of Biorithm Research Kit Versus CTG in Prenatal Monitoring of Pregnant Participants.

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Cardiovascular, Metabolic Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

1 pipeline

Metabolic Diseases

1 pipeline

Marketed

Pipeline